NTT DATA signs non-exclusive license to resell DATATRAK ONE in the Chinese market

DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced NTT DATA signed a non-exclusive license to resell DATATRAK ONE™ in the Chinese market. 

As an existing value-added reseller of DATATRAK ONE™ and Enterprise Transfer services within the Japanese market, NTT DATA extends its reach into China to deliver clinical trials with DATATRAK's cloud-based unified research platform. NTT DATA will be designing and delivering electronic clinical trials under this multi-year agreement. An added benefit of the strategic partnership is the ability to leverage NTT DATA's existing offices in China and experts to accelerate the penetration of the Chinese market.

"NTT DATA is proud to expand its global footprint by executing its Pan Asia strategy through the use of DATATRAK ONE™," commented Hidenori Chihara, NTT DATA's Senior Executive Manager Healthcare Division.  "As evident by the attendance and content of last week's DIA meeting in Shanghai, China is becoming a dynamic emerging country in the Pharmaceutical industry.  Together with DATATRAK, we are positioned to be the leader in both local and global clinical trials in China."

"This agreement creates a Pan Asian powerhouse that allows for both global companies and local Chinese companies to take advantage of our unified software suite," stated Laurence P. Birch, DATATRAK's Chairman of the Board and CEO. "We are excited about the opportunities the strategic partnership will bring as we expand the continued combination of DATATRAK's superior technology and NTT DATA's world class delivery services into the Chinese market."

DATATRAK ONE™ is a comprehensive cloud-based global clinical research platform helping customers with the strategy, planning and management of their entire life science product portfolio, including resource management, study execution needs and safety reporting.